(EMAILWIRE.COM, April 02, 2019 ) The cell therapy technologies market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4%. Factors such as rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are driving the growth of this market.

Consumables segment to account for the largest share of the cell therapy instruments market, by product

On the basis of product, the market is segmented into consumables, equipment, and systems & software. The consumables segment is expected to account for the largest share of the cell therapy instruments market in 2018. The large share of this segment is attributed to the high demand for consumables (such as growth factors and media) in cell-based experiments and cancer research and the growing number of new product launches. Moreover, consumables are required at every step of cell processing. This is further expected to drive their adoption in the market.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978

Cell processing segment dominates the cell therapy instruments market in 2018; this trend to continue during the forecast period

On the basis of process, the market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control. The cell processing segment is expected to account for the largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period. The cell processing stage makes the highest use of cell therapy instruments and media, especially during culture media processing. This is a major factor responsible for the large share and high growth of this segment.

North America to hold the largest share of the cell therapy instruments market in 2018

The market, by region, is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of this market in 2018. The large share of this regional segment can primarily be attributed to the high burden of chronic diseases and increasing R&D activities in pharmaceutical and biotechnology industries.

The market is dominated by players such as Beckman Coulter, Inc. (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT, Inc. (US), and Thermo Fisher Scientific, Inc. (US).